TD Cowen Remains a Buy on Medline (MDLN)
In a report released yesterday, Charles Rhyee from TD Cowen maintained a Buy rating on Medline, with a price target of $46.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Rhyee is a 3-star analyst with an average return of 2.6% and a 49.39% success rate. Rhyee covers the Healthcare sector, focusing on stocks such as Cardinal Health, Cigna, and Option Care Health.
In addition to TD Cowen, Medline also received a Buy from Citi’s Patrick B Donnelly in a report issued today. However, on the same day, Deutsche Bank maintained a Hold rating on Medline (NASDAQ: MDLN).
Based on Medline’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $7.79 billion and a net profit of $180 million.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MDLN in relation to earlier this year. Most recently, in December 2025, Carlyle Mozart Coinvestment Holdings, L.P., a Major Shareholder at MDLN sold 19,136,333.00 shares for a total of $554,953,657.00.
Read More on MDLN:
